Literature DB >> 27259050

Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L.

Dong-Hui Chen1, Jennifer E Below2, Akiko Shimamura3, Sioban B Keel4, Mark Matsushita5, John Wolff5, Youngmee Sul5, Emily Bonkowski1, Maria Castella6, Toshiyasu Taniguchi6, Deborah Nickerson2, Thalia Papayannopoulou4, Thomas D Bird7, Wendy H Raskind8.   

Abstract

Ataxia-pancytopenia (AP) syndrome is characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition to marrow failure and myeloid leukemia, sometimes associated with monosomy 7. Here, in the four-generation family UW-AP, linkage analysis revealed four regions that provided the maximal LOD scores possible, one of which was in a commonly microdeleted chromosome 7q region. Exome sequencing identified a missense mutation (c.2640C>A, p.His880Gln) in the sterile alpha motif domain containing 9-like gene (SAMD9L) that completely cosegregated with disease. By targeted sequencing of SAMD9L, we subsequently identified a different missense mutation (c.3587G>C, p.Cys1196Ser) in affected members of the first described family with AP syndrome, Li-AP. Neither variant is reported in the public databases, both affect highly conserved amino acid residues, and both are predicted to be damaging. With time in culture, lymphoblastic cell lines (LCLs) from two affected individuals in family UW-AP exhibited copy-neutral loss of heterozygosity for large portions of the long arm of chromosome 7, resulting in retention of only the wild-type SAMD9L allele. Newly established LCLs from both individuals demonstrated the same phenomenon. In addition, targeted capture and sequencing of SAMD9L in uncultured blood DNA from both individuals showed bias toward the wild-type allele. These observations indicate in vivo hematopoietic mosaicism. The hematopoietic cytopenias that characterize AP syndrome and the selective advantage for clones that have lost the mutant allele support the postulated role of SAMD9L in the regulation of cell proliferation. Furthermore, we show that AP syndrome is distinct from the dyskeratoses congenita telomeropathies, with which it shares some clinical characteristics.
Copyright © 2016 American Society of Human Genetics. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27259050      PMCID: PMC4908176          DOI: 10.1016/j.ajhg.2016.04.009

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  74 in total

1.  Parametric and nonparametric linkage analysis: a unified multipoint approach.

Authors:  L Kruglyak; M J Daly; M P Reeve-Daly; E S Lander
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

2.  Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome.

Authors:  Hiroki Yamaguchi; Gabriela M Baerlocher; Peter M Lansdorp; Stephen J Chanock; Olga Nunez; Elaine Sloand; Neal S Young
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

3.  Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity.

Authors:  Michael Y Zhang; Siobán B Keel; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Amanda C Watts; Colin C Pritchard; Stephen J Salipante; Michael R Jeng; Inga Hofmann; David A Williams; Mark D Fleming; Janis L Abkowitz; Mary-Claire King; Akiko Shimamura
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

4.  Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.

Authors:  Andres Jerez; Yuka Sugimoto; Hideki Makishima; Amit Verma; Anna M Jankowska; Bartlomiej Przychodzen; Valeria Visconte; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Austin G Kulasekararaj; Andrea Pellagatti; Kathy McGraw; Hideki Muramatsu; Alison R Moliterno; Mikkael A Sekeres; Michael A McDevitt; Seiji Kojima; Alan List; Jacqueline Boultwood; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-05-02       Impact factor: 22.113

5.  Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Elaine M Sloand; Olga Nunez; Neal S Young
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

Review 6.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

Review 7.  Molecular pathogenesis of Fanconi anemia: recent progress.

Authors:  Toshiyasu Taniguchi; Alan D D'Andrea
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

Review 8.  Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder.

Authors:  Galina Glousker; Fabien Touzot; Patrick Revy; Yehuda Tzfati; Sharon A Savage
Journal:  Br J Haematol       Date:  2015-05-04       Impact factor: 6.998

9.  Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse.

Authors:  Catherine F Li; Jeffrey R MacDonald; Robert Y Wei; Jocelyn Ray; Kimberly Lau; Christopher Kandel; Rachel Koffman; Sherilyn Bell; Stephen W Scherer; Benjamin A Alman
Journal:  BMC Genomics       Date:  2007-04-03       Impact factor: 3.969

10.  Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.

Authors:  Agata Smogorzewska; Shuhei Matsuoka; Patrizia Vinciguerra; E Robert McDonald; Kristen E Hurov; Ji Luo; Bryan A Ballif; Steven P Gygi; Kay Hofmann; Alan D D'Andrea; Stephen J Elledge
Journal:  Cell       Date:  2007-04-05       Impact factor: 41.582

View more
  59 in total

1.  A novel germline SAMD9L mutation in a family with ataxia-pancytopenia syndrome and pediatric acute lymphoblastic leukemia.

Authors:  Jesse J C Cheah; Anna L Brown; Andreas W Schreiber; Jinghua Feng; Milena Babic; Sarah Moore; Chun-Chun Young; Miriam Fine; Kerry Phillips; Michael Guandalini; Peter Wilson; Nicola Poplawski; Christopher N Hahn; Hamish S Scott
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

2.  Multiorgan failure with abnormal receptor metabolism in mice mimicking Samd9/9L syndromes.

Authors:  Akiko Nagamachi; Akinori Kanai; Megumi Nakamura; Hiroshi Okuda; Akihiko Yokoyama; Satoru Shinriki; Hirotaka Matsui; Toshiya Inaba
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

Review 3.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

4.  DOMINO: Using Machine Learning to Predict Genes Associated with Dominant Disorders.

Authors:  Mathieu Quinodoz; Beryl Royer-Bertrand; Katarina Cisarova; Silvio Alessandro Di Gioia; Andrea Superti-Furga; Carlo Rivolta
Journal:  Am J Hum Genet       Date:  2017-10-05       Impact factor: 11.025

Review 5.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 6.  Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes.

Authors:  Allison H West; Jane E Churpek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Genetic predisposition to MDS: diagnosis and management.

Authors:  Elissa Furutani; Akiko Shimamura
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 8.  Germline Genetic Predisposition to Hematologic Malignancy.

Authors:  Elissa Furutani; Akiko Shimamura
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

9.  POLQ suppresses interhomolog recombination and loss of heterozygosity at targeted DNA breaks.

Authors:  Luther Davis; Kevin J Khoo; Yinbo Zhang; Nancy Maizels
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-01       Impact factor: 11.205

Review 10.  Familial myelodysplastic syndrome/acute myeloid leukemia.

Authors:  Jane E Churpek
Journal:  Best Pract Res Clin Haematol       Date:  2017-10-04       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.